Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 over exp |
Therapy | Cemiplimab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 over exp | lung non-small cell carcinoma | sensitive | Cemiplimab | Guideline | Actionable | Libtayo (cemiplimab) is included in guidelines as preferred first-line therapy for patients with advanced or metastatic non-small cell lung cancer, not otherwise specified, with CD274 (PD-L1) expression of at least 50% and negative for actionable molecular biomarkers; and as continued maintenance therapy (NCCN.org). | detail... |
CD274 over exp | lung non-small cell carcinoma | sensitive | Cemiplimab | Phase III | Actionable | In a phase III trial (EMPOWER-Lung 1), Libtayo (cemiplimab) therapy improved overall survival (18.7 vs 11.7 mo, HR 0.17, p=0.0091), progression-free survival (10.4 vs 5.3 mo, HR 0.45, p=0.0231), and objective response rate (41.2% vs 8.8%) compared to chemotherapy in patients with advanced non-small cell lung cancer with CD274 (PD-L1) expression equals to or over 50% and with brain metastases at baseline (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 9085-9085; NCT03088540). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... | |
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis. | Full reference... |